FRANKLIN, Tenn--(BUSINESS WIRE)--BioMimetic Therapeutics, Inc. (BMTI) today announced interim results for the use of GEM OS1™ Bone Graft in the Company’s first orthopedic clinical trial in Canada for foot and ankle fusion indications. Lead Canadian investigator, Timothy R. Daniels, M.D., presented the results on Saturday, November 4th at the Dewar Orthopaedic Society Meeting. Dr. Daniels made the following observations during his presentation:
